Absorica LD™, a lower dose version of Absorica™ capsule (isotretinoin), has been made available by Sun Pharmaceuticals for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5mm or greater.
Absorica LD contains micronized isotretinoin, which the Company states allows for optimized absorption at a 20% lower dose. The treatment is not substitutable with other available isotretinoin products, including Absorica, because of different bioavailability and recommended dosage.
Absorica LD contains a Boxed Warning for embryo-fetal toxicity and is contraindicated in pregnancy. Due to the risk of embryo-fetal toxicity, the treatment is only available through a Risk Evaluation and Mitigation Strategy (REMS) program called iPLEDGE. Because of
significant adverse reactions associated with its use, Absorica LD should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics.
Absorica LD is available in 8mg, 16mg, 20mg, 24mg, 28mg, and 32mg capsule strengths and can be taken with or without food. Although Absorica and Absorica LD have a 20mg strength, these strengths have different bioavailability and are not substitutable.
For more information visit absoricald.com.
This article originally appeared on MPR